Clinical/Research Interests

Dr. Evans' practice is dedicated to the management of patients with urologic malignancies. He works with medical oncologists and radiation oncologists to provide multimodal approaches to cancer therapy. His surgical expertise includes robotic assisted laparoscopic radical prostatectomy with nerve sparing, complex renal surgery to include partial nephrectomy and vena cava thrombectomy, cystectomy with extended pelvic lymph node dissection and urinary diversion with orthotopic neobladders. Dr. Evans also has expertise in treating patients with metastatic testicular cancer and performing retroperitoneal lymph node dissection in post chemotherapy patients.

Dr. Evans' research laboratory focuses on prostate cancer; specifically, mechanisms signaling the androgen receptor to activate prostate cancer growth and progression following castration. His laboratory has developed models to study this and has identified novel mechanisms that activate the androgen receptor. His laboratory work has tested new agents and brought them from bench studies to animal models to clinical trials.

Dr. Evans' philosophy of care is to fully assess the patient's medical condition including how it relates to family and social circumstances, educate the patient fully about their disease process and include the patient in the decision making process that best suits the outcomes they seek. In each case he looks for opportunity to enroll them in any new therapies or clinical trials that may be available and pertinent.

Specialty:

Center/Program Affiliation:

Address:

Alternate Address

Other Languages:

Education:

Internships:

Residency:

Fellowships:

Board Certifications:

Professional Memberships:

Select Recent Publications:

Feng S., Tang Q., Sun M., Chun J.Y., Evans C.P., Gao A.C. Mol Cancer Therapy. Interleukin-6 Increases Prostate Cancer Cells Resistance to Bicalutamide Via TIF2. 8: 665-71. 2009.

Lara, P.N. Jr., Longmate, J, Evans, C.P., Quinn, D.I., Twardowski, P., Chatta, G, Posadas, E, Stadler, W., Gandara, D.R. A Phase II Trial of the Src-Kinase Inhibitor AZD0530 in Patients with Advanced Castration-Resistant Prostate Cancer: A California Cancer Consortium Study. Anti-Cancer Drugs. 20: 179-84. 2009.

Yang, J.C., Busby, J.E., OK, J., Borowsky, A.D., Kung, H-J., Evans, C.P. Aberrant Activation of Androgen Receptor in a New Neuropeptide-Autocrine Model of Androgen-Insensitive Prostate Cancer. Cancer Res. 69: 151-60. 2009.

Evans C.P., Identification of Molecular Targets in Urologic Oncology. World J Urol. Nov 12 Epub. 2008.

Chang Y-M, Bai L, Yang J.C., Kung H-J, Evans C.P. Src Family Kinase Oncogenic Potential and Pathways in Prostate Cancer As Revealed By AZD0530. Oncogene. Nov 6; 27(49): 6365-75. 2008.

Nelson E.C. Rodriguez R.L., Dawson K., Galvez A.F., Evans C.P. The Interaction of Genetic Polymorphisms with Lifestyle Factors: Implications for the Dietary Prevention of Prostate Cancer. Nutr Cancer. 60: 301-12. 2008.

Ramirez, M.L., Nelson, E.C., deVere White, R.W., Lara, P.N., Evans, C.P. Current Applications for Prostate-Specific Antigen Doubling Time. Eur Urol. Aug; 54(2): 291-302. 2008.

Ramirez M.L., Nelson E.C., Evans C.P. Beyond Prostate-Specific Antigen: Alternate Serum Markers. Prostate Cancer Prostatic Diseases. 11: 216-29. 2008.

Gautschi O., Tepper C.G., Purnell P.R., Izumiyq Y., Evans C.P., Green T.P., Desprex P.Y., Lara P.N., Gandara D.R., Mack P.C., Kung H-J. Regulation of Id1 Expression by Src in Cancer: Implications for Targeting of the Bone Morphogenetic Protein Pathway. Cancer Research. 68: 2250-8. 2008.

Shi XB, Xui L, Yang JC, MA A, Zhao J, Ma X, Tepper CG, Evans CP, Kung HJ, deVere White R. An Androgen-Regulated miRNA Suppresses Bak1 Expression and Induces Androgen-Independent Growth of Prostate Cancer Cells. PNAS 104: 19983-8. 2007.